TEM8/ANTXR1 Therapeutic Antibodies

About BioMed Valley Discoveries

BioMed Valley Discoveries is a privately held, clinical-stage biotech with a novel operational and funding structure, wholly owned by a supporting organization of the non-profit Stowers Institute for Medical Research. This setup provides stable capital, allowing the company to pursue risk-tolerant, early-stage translational and clinical programs in oncology and other serious diseases. Its most advanced candidate is ulixertinib, a first-in-class ERK1/2 inhibitor, with a Phase 2 trial ongoing in histiocytosis and other MAPK-driven cancers. The company's strategy is to de-risk assets through clinical proof-of-concept and then partner them for later-stage development and commercialization.

Therapeutic Areas